The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?
Powles
Thomas
T
St Bartholomew's Hospital, London, UK. Thomas.Powles@bartsandthelondon.nhs.uk
Jones
Rob
R
Chowdhury
Simon
S
Shamash
Jonathan
J
Mantle
Mark
M
Lim
Louise
L
Hutson
Tom
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D017277:Drug Approval; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011758:Pyrroles / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077210:Sunitinib; D006113:United Kingdom
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus